Down 33%, this could be the ASX 200's best value stock

Value investors could overlook this opportunity if they focus solely on the earnings multiple.

| More on:
A woman looks shocked as she drinks a coffee while reading the paper.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

While the S&P/ASX 200 Index (ASX: XJO) is roughly in line with its historical price-to-earning (P/E) ratio, dozens of quality companies are trading at a discount to the renowned Australian sharemarket measuring stick.

However, 'value' is more than earnings multiple, in my opinion. I try to take a holistic approach when I'm hunting for value among ASX shares — considering balance sheet strength, management quality, future cash flows, and competitive advantages.

When factoring in the range of fundamentals, I'd argue there is one company that emerges as a cut above the rest right now.

An ASX 200 company with charming fundamentals

Without further ado, the company presently atop my buying list is ResMed CDI (ASX: RMD). This industry leader is known for its medical devices for treating sleep apnea and other respiratory conditions.

At an earnings multiple of 23 times, ResMed may not look the 'cheapest' or most value-orientated opportunity among ASX 200 shares. But, these multiples are nearly useless when viewed in isolation.

For example, paying a premium for a company growing its profits at a faster-than-average pace can make sense. Likewise, a business with a more robust financial standing (i.e. less debt, more cash) is oftentimes more valuable than a heavily indebted one.

ASX 200 IndexResMed
P/E Ratio~17~23
Revenue Growth (1-year)10.4%20.7%
Gross Profit Margin25.7%54.4%
Net Income Margin11.3%20.7%
Net Income Growth (1-year)-35.0%15.3%
Debt-to-equity Ratio163.6%32%
Return on Equity (past year)11.2%21.3%
Data as of 14 November 2023

As the table above shows, ResMed fundamentally appears like a higher quality company than the ASX 200 Index average. Whether it's the juicier gross margin, better growth rates, or lower debt exposure, this business is exceptional in many regards.

Slimmed down valuation

Despite the enticing fundamentals, the Resmed share price has been gasping for air for the past few months. Shares in the ASX 200 healthcare company are now down 33% compared to a year ago, sliding to their lowest level since pre-2020.

We can comfortably assume the downfall is related to the emergence of weight-loss drugs, such as Ozempic, Wegovy, and Mournjaro. I say 'comfortably' because the company's revenue and profits have only increased over the past 12 months.

Not long ago, ResMed traded on a P/E ratio of 40 to 50 times earnings. As Ozempic has become popular (shown above), investor fears have grown of the drug's perceived role in reducing sleep apnea. However, ResMed and sleep apnea are yet to show marked impacts from this.

Why I see a potentially fruitful investment

The sleep apnea industry is vast. Some 936 million adults around the world are estimated to have mild to severe obstructive sleep apnea, according to The National Council of Aging. ResMed has only scratched the surface, with approximately 22.5 million connected devices sold to date in 2023.

Furthermore, demand for treating sleep apnea is still forecast to grow to 1.2 billion people worldwide by 2050, even when assuming a 15% reduction due to weight-loss drugs.

These figures are based on ResMed's own internal studies, so make of that what you will. Though, I personally believe it could be roughly accurate. It's hard to imagine these 'wonder drugs' will suit everyone, potentially giving ResMed more room to grow than many investors are factoring in.

As such, I'm primed and ready to scoop up more of this ASX 200 share at my next available opportunity.

Motley Fool contributor Mitchell Lawler has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Opinions

Happy young couple saving money in piggy bank.
Opinions

Want to start investing in ASX shares? Here's what I'd buy

This is where I’d begin to put my money in the stock market.

Read more »

People of different ethnicities in a room taking a big selfie, symbolising diversification.
Opinions

Want diversification? Get it instantly with these ASX 200 shares

Some businesses offer a lot more diversification than others.

Read more »

A happy man and woman on a computer at Christmas, indicating a positive trend for retail shares.
Opinions

2 ASX 200 shares I'd want to receive as a present today

Merry Christmas! Are there any stocks under your tree?

Read more »

Young boy in business suit punches the air as he finishes ahead of another boy in a box car race.
Opinions

Why I think these 2 ASX 300 stocks will beat the market in 2025

I’m very optimistic about a few ASX growth shares.

Read more »

A businessman compares the growth trajectory of property versus shares.
Opinions

What's the outlook for shares vs. property in 2025?

The experts have put out their new year predictions...

Read more »

Cheerful boyfriend showing mobile phone to girlfriend in dining room. They are spending leisure time together at home and planning their financial future.
Opinions

My ASX share portfolio is up 30% this year! Here's my plan for 2025

The best investing plans shouldn't need too many updates.

Read more »

Man in an office celebrates at he crosses a finish line before his colleagues.
Opinions

These stocks made my share portfolio a market-beater in 2024

Beating the market is the least important takeaway from this year.

Read more »

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
Opinions

2 underappreciated ASX 200 shares to buy now

Investors may be undervaluing these ASX 200 shares heading into 2025, according to this expert.

Read more »